Gwo Xi Stem Cell Applied Technology recently received notification from its clinical trial partner VRISG (Vinmec Research Institute of Stem Cell and Gene Technology) that its stem cell therapy for diabetes, GXIPC1, has completed enrollment of all subjects and stem cell infusions at Vinmec Times City International Hospital in Vietnam.
Gwo Xi Stem Cell Applied Technology's new drug GXIPC1 is a Phase I clinical trial aimed at evaluating its safety, tolerability, and preliminary efficacy in patients with diabetes. This is an off-the-shelf stem cell preparation that can be immediately used, facilitating cross-border transportation through a sophisticated stem cell drug cold chain transport system, significantly reducing waiting times for cell preparation during patient treatment.
Gwo Xi Stem Cell Applied Technology's GXIPC1 is a cross-border allogeneic stem cell new drug that has received special approval for clinical trials in Vietnam. The clinical trial conducted this time is in collaboration with VRISG, the medical arm of Vietnam's largest conglomerate, Vingroup, and is Joint Commission International (JCI) certified.
The trial, provided with GXIPC1 stem cell preparations manufactured by GWO XI STEM CELL APPLIED TECHNOLOGY and combined with Vingroup's medical capabilities in Vietnam, aims to explore clinical medical research on stem cell therapy for diabetes. It encompasses important goals such as trial application, cross-border transportation of stem cell drugs via cold chain, comprehensive quality control throughout the process, clinical trial execution, documentation, and follow-up.
According to the latest statistics from the International Diabetes Federation (IDF), there are approximately 537 million diabetes patients worldwide, estimated to rise to 783 million by 2045. Vietnam is among the countries with the fastest-growing diabetes patient population, with the number of patients doubling to 4 million in the past decade.
Taiwan's regenerative medicine has flourished in recent years, with hopes that the completion of the "Regenerative Medicine Second Act" legislation will strengthen the professional division of medical and industrial ends, encouraging the regenerative medicine industry to move towards allogenic, automated, and mass production. It is expected to further drive the development of Taiwan's regenerative medicine and become another highlight industry.
Resource (Mandarin):
